Synonyms: LCQ-908 | LCQ908
Compound class:
Synthetic organic
Comment: Pradigastat is a potent and selective inhibitor of diacylglycerol O-acyltransferase 1 (DGAT1).
The PubChem CID 53387035 shows the molecule with no stereochemistry. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Pradigastat has been granted orphan designation by the EMA (in 2012) and US FDA, for the treatment of familial chylomicronaemia syndrome (type-I hyperlipoproteinaemia). Pradigastat (under research code LCQ908) has completed a Phase 2 clinical trial for type 2 diabetes (NCT00901979). A Phase 2 trial for coronary artery disease associated with hypertriglyceridemia is recruiting patients (NCT01474434), as is a Phase 2I trial for familial chylomicronemia syndrome (NCT01589237) (as of Nov 2014). |